Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read More
Pierre-Alain is a graduate of the University of Lausanne, Department of Plant Biochemistry, in Switzerland, where he also received his PhD, Early in his career, Pierre-Alain completed a postdoctoral fellowship at the University of Wisconsin-Madison in the degradation of proteins by the ubiquitin pathway. He returned to Switzerland in 1993, where he discovered a family of genetic sequences that are involved in the epigenetic regulation of genes. This discovery has subsequently been used to express therapeutic proteins in pharma and biotech. Pierre-Alain has served Selexis as CSO since 2006.
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.